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Site-directed mutagenesis and gene replacement
were used to inactivate two ketoreductase (KR)
domains within the amphotericin polyketide syn-
thase in Streptomyces nodosus. The KR12 domain
was inactivated in the DamphNM strain, which
produces 16-descarboxyl-16-methyl-amphotericins.
The resulting mutant produced low levels of the
expected 15-deoxy-15-oxo analogs that retained
antifungal activity. These compounds can be useful
for further chemical modification. Inactivation of the
KR16 domain in thewild-type strain led to production
of 7-oxo-amphotericin A and 7-oxo-amphotericin B
in good yield. 7-oxo-amphotericin B was isolated,
purified, and characterized as the N-acetyl methyl
ester derivative. 7-oxo-amphotericin B had good
antifungal activity and was less hemolytic than am-
photericin B. These results indicate that modification
at the C-7 position can improve the therapeutic index
of amphotericin B.INTRODUCTION
Amphotericin B is a medically important antifungal antibiotic that
is produced by Streptomyces nodosus (Lemke et al., 2005). Like
other polyenemacrolides, amphotericin B acts by interacting se-
lectively with ergosterol in fungal cells to form transmembrane
channels. Amphotericin B has several other biological activities
that result from interactions with sterols in other cell membranes.
It is active against enveloped viruses, protozoan parasites, and
pathogenic prion proteins (Lemke et al., 2005; Hartsel and Bo-
lard, 1996). Low doses of amphotericin B reactivate the latent
state of HIV in macrophages, and could deplete pools of provi-
ruses that are insensitive to antiretroviral drugs (Jones et al.,
2005). When administered as a drug, amphotericin B has serious
side effects, primarily nephrotoxicity, due to its lowwater solubil-
ity, interactions with cholesterol in human cell membranes, and
its facile oxidation to form reactive species that damage cells
(Abu-Salah, 1996; Schaffer, 1984). The considerable and wide-78 Chemistry & Biology 15, 78–86, January 2008 ª2008 Elsevier Ltdranging therapeutic potential of amphotericin B has not been
fully exploited because of its toxicity. The adverse effects can
be moderated by encapsulating the drug in liposomes or lipid
complexes (Lemke et al., 2005). However, these lipid formula-
tions have residual toxicity and their use is limited by their ex-
pense. With the rapid worldwide increase in incidence of life-
threatening systemic fungal infections, there is an urgent need
for a commercially viable nontoxic analog of amphotericin B
that retains its antifungal activity.
Several analogs have been made by chemical modification of
the natural product. These have provided the first insights into
structure-activity relationships and indicate how toxicity might
be reduced. The series of conjugated double bonds is essential
for antibiotic activity (Cereghetti and Carreira, 2006). Suppres-
sion of charge on the exocyclic carboxyl group increases spec-
ificity for ergosterol over cholesterol (Cheron et al., 1988). Deriv-
atization of mycosamine can improve the therapeutic index,
provided that the amino group retains a positive charge (Szlin-
der-Richert et al., 2001; Paquet and Carreira, 2006; Ehren-
freund-Kleinman et al., 2002). Modification at the C-13 hemiketal
reduces hemolytic activity with a slight decrease in antifungal
activity (Taylor et al., 1992). Fluorine atoms introduced at C-14
or C-28 do not affect activity, and will be valuable in detailed
studies of the mode of action (Matsumori et al., 2005; Tsuchi-
kawa et al., 2006). However, there have been no synthetic stud-
ies enabling investigation of effects of alterations on the polyol
part of the molecule from C-2 through to C-11 or at C-15.
Recently, amphotericin analogs have been produced by ma-
nipulation of biosynthetic genes in S. nodosus. The macrolac-
tone core of amphotericin B is assembled by a modular polyke-
tide synthase (PKS) (Caffrey et al., 2001). Each extensionmodule
contains acyltransferase (AT), 3-oxoacylsynthase (KS), and acyl
carrier protein (ACP) domains that generate a new 3-oxoacyl in-
termediate. In most cycles, 3-oxoacyl reductase (KR) domains
catalyze formation of 3-hydroxyacyl groups. Dehydratase (DH)
domains may then catalyze dehydration of 3-hydroxyacyl chains
to form 2-enoyl intermediates which may be further reduced by
enoyl reductase (ER) domains. S. nodosus produces a mixture
of the heptaene amphotericin B (1) and the tetraene amphoteri-
cin A (2) (Figure 1), suggesting that the ER5 domain only acts on
some of the nascent oligoketide chains. Completed chains
lactonize and then undergo three late post-PKS modifications:All rights reserved
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Biosynthesis of Oxo-Amphotericinsa methyl branch at C-16 is oxidized to a carboxyl group by a cy-
tochrome P450, a mycosaminyl sugar residue is attached at
C-19, and a hydroxyl group is introduced atC-8 (Byrne et al., 2003).
The first analogs generated by engineered biosynthesis were
obtained by inactivation of late genes. Similar work has been car-
ried out on the streptomycetes that produce the related polyenes
pimaricin, nystatin, candicidin, and rimocidin (Aparicio et al.,
2003; Seco et al., 2005). De-epoxypimaricin, 10-deoxy-nystatin,Figure 1. Structures and Relative Molecular
Masses of Amphotericin B, Amphotericin
Analogs, and Related Polyenes
and 8-deoxy-amphotericin B, obtained
by inactivation of cytochrome P450 hy-
droxylase genes, retained antifungal
activity (Mendes et al., 2001; Volokhan
et al., 2006; Byrne et al., 2003). Disruption
of an S. nodosus gene encoding a differ-
ent cytochrome P450 resulted in 16-des-
carboxyl-16-methyl-amphotericins that
retained antifungal activity and had low
hemolytic activity (Carmody et al., 2005).
Similar improvements were also seen
with rimocidin and tetraeneCE-108 deriv-
atives that have amideormethyl groups in
place of exocyclic carboxyl groups (Seco
et al., 2005). Disruption of mycosamine
biosynthetic genes gave the aglycone 8-
deoxy-amphoteronolide A (Byrne et al.,
2003) and an analog glycosylated with
a neutral deoxyhexose (Carmody et al.,
2005).
New polyenes have also been gener-
ated by engineering PKS genes. A pen-
taene analog of amphotericin B was inac-
tive (Carmody et al., 2004), and a hexaene
derivative of nystatin had reduced activity
(Brautaset et al., 2002). Zotchev and co-
workers introduced hydroxyl groups into
the polyene unit of nystatin by inactivating
DH3 and DH4 of the PKS. The resulting
33- and 35-hydroxy-nystatins showed in-
creased water solubility but dramatically
reduced antifungal activity (Borgos et al.,
2006).
This study aimed to explore further the
range of analogs that can be obtained by
genetic engineering. Inactivation of PKS
KRdomains has the effect of replacing al-
kane, alkene, or hydroxyl groups with ke-
tone groups. These analogs will be useful
in investigating structure-activity relation-
ships and also because newly introduced
carbonyl groups can be chemically mod-
ified to introduce a wide range of steric,
solvation, or electronic alterations to the
molecule. The various KR domains inChemistry & Biologythe amphotericin PKS were considered to identify optimal tar-
gets for inactivation. The hydroxyl groups introduced by many
of these domains are essential for macrolactone formation
(KR1), biosynthesis of the polyene unit (KR3–KR9), glycosylation
(KR10), and formation of the hemiketal ring (KR11). The hydroxyl
group introduced by KR2 is important for stable transmembrane
channel formation (James and Rawlings, 1996). Because modi-
fications of the polyol chain have not been fully investigated,15, 78–86, January 2008 ª2008 Elsevier Ltd All rights reserved 79
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Biosynthesis of Oxo-Amphotericinsthe domains chosen for initial inactivation were KR12 and KR16.
Inactivation of KR12 should give 15-deoxy-15-oxo-amphoteri-
cins 3 and 4, whereas inactivation of KR16 should give 7-oxo-
amphotericins 7 and 8 (Figure 1; see also the Supplemental
Data available with this article online). This study aimed to inves-
tigate whether engineered biosynthesis could deliver these com-
pounds in quantities sufficient for purification, characterization,
and bioassay. A ketone group at C-15 would allow chemical
modification of the polar end of the molecule, for example to in-
crease the water solubility and decrease the aggregation found
in serum. In addition, 15-deoxy-15-oxo-amphotericins might de-
carboxylate chemically to yield useful analogs with no substitu-
ent at C-16. Introduction of a ketone group at C-7 would allow
further chemical modifications that could increase the polarity
of the polyol chain without eliminating antifungal activity.
RESULTS
Strategy for Inactivation of KR Domains
Studies on other modular PKSs indicate that extensive deletions
from PKS domains can result in low product yields, possibly
because correct folding of the multienzyme polypeptides is im-
paired. Point mutations that replace active site residues can in-
activate domains without causing structural disruption. Reid
and coworkers inactivated KR6 in 6-deoxy-erythronolide B syn-
thase by replacing an active site tyrosine with phenylalanine, and
obtained good yields of the expected 3-oxo analog (Reid et al.,
2003). Here, this approach was used with the amphotericin
PKS. The KR12 domain is located within the hexamodular AmphI
protein and the KR16 domain is located within the trimodular
AmphJ protein. The strategy for KR12 inactivation aimed to
change the DNA sequence around the active site tyrosine codon
from GGC-AAC-TAC to GGA-AGC-TTC. This would replace the
TAC codon (for tyrosine 6165 of AmphI) with TTC for phenylala-
nine. Introduction of a HindIII restriction site (AAGCTT) changes
the preceding GGC-AAC codons for glycine and asparagine to
GGA-AGC for glycine and serine. The asparagine / serine
change was expected to be neutral because many KR domains
have serine at this position (Caffrey, 2003). A similar strategy wasFigure 2. ESMS Analysis of Tetraene-En-
riched Extract from S. nodosus DNM-KR12
Analyses in positive and negative ion modes are
shown in (A) and (B), respectively. Themajor peaks
at 878.8 (A) and 876.7 (B) are consistent with
16-descarboxyl-8,15-dideoxy-16-methyl-15-oxo-
amphotericin A (6) ([M + H]+ = 878.5; [M – H] =
876.5). The peaks at 894.8 (A) and 892.7 (B)
correspond to the C-8 hydroxylated form of this
compound. The peaks at 892.8 (A) and 890.7
([B], indicated by triangle) correspond to the
heptaene 16-descarboxyl-15-deoxy-16-methyl-15-
oxo-amphotericin B (5).
designed for inactivation of KR16. The aim
was to replace the GCC-AAC-TAC se-
quence around the active site tyrosine
codon (tyrosine 720 of AmphJ) with GCA-
AGC-TTC. This would introduce the same80 Chemistry & Biology 15, 78–86, January 2008 ª2008 Elsevier Ltdchanges as those in the mutated KR12 coding sequence, except
that a GCA alanine codon replaces a GCC alanine codon. Intro-
duction of GGA and GCA codons was not expected to impair
translation of PKS genes because amphI contains 68 GGA co-
dons and amphJ contains 19 GCA codons.
PCR mutagenesis was used to construct plasmids containing
the engineered KR12 and KR16 coding sequences. The details
of these constructions are shown in Figures S1–S3. The two mu-
tated DNA sequences were cloned into phage KC-UCD1 to give
recombinant phages KC-KR12 and KC-KR16. These were used
to introduce the engineered DNA into S. nodosus to allow gene
replacement by homologous recombination.
Inactivation of KR12
Homologous recombination in polyene-producing streptomy-
cetes can be unpredictable (Aparicio et al., 2003; Volokhan
et al., 2006), and attempts to replace the KR12 coding sequence
in wild-type S. nodosus were not successful (see Experimental
Procedures). However, this gene replacement was relatively
straightforward in strain DNM, which lacks the amphN cyto-
chrome P450 gene and amphM ferredoxin gene and produces
16-descarboxyl-16-methyl-amphotericin B and 8-deoxy-16-
descarboxyl-16-methyl-amphotericin A (Carmody et al., 2005).
Gene replacement mutants were identified by amplifying the
KR12 coding region and by testing for the presence of a HindIII
site (Figure S4). The resulting S. nodosus DNM-KR12 double
mutants gave only trace levels of tetraene or heptaene produc-
tion. Yields were increased by including glycerol (100 mM) and
Amberlite XAD16 resin (5% w/v) in the production medium. Un-
der these conditions, the yields were 8 mg tetraene and 4 mg
heptaene per liter. Themethanolic extract from the sedimentable
fraction of the culture was concentrated in vacuo and chromato-
graphed on a Sephadex LH20 column to give a tetraene fraction
that contained some heptaene and an impure heptaene fraction
that was free of tetraene. Analysis by electrospray mass spec-
trometry (ESMS) (Figure 2) indicated that the tetraene-enriched
fraction contained a major species with a mass appropriate for
16-descarboxyl-8,15-dideoxy-16-methyl-15-oxo-amphotericin
A (6) ([M + H]+ = 878.8; [M – H] = 876.7). A dehydrated form of 6All rights reserved
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Biosynthesis of Oxo-Amphotericins([M + H]+ = 860.8) was detected in positive ion mode only. Minor
species had masses appropriate for the C-8 hydroxylated form
of 6, 15-deoxy-16-descarboxyl-16-methyl-15-oxo-amphotericin
A ([M + H]+ = 894.8; [M – H] = 892.7). The sample also contained
peaks appropriate for the heptaene 15-deoxy-16-descarboxyl-
16-methyl-15-oxo-amphotericin B (5) ([M + H]+ = 892.8;
[M – H] = 890.7). These peaks were also detected in the hep-
taene-enriched sample (not shown). No traces of aglycones
were detected, suggesting that the introduction of a ketone
group at C-15 does not impair glycosylation by AmphDI.
High-resolutionESMSgave themolecular formulaC47H75NO14
for the major tetraene (observed mass = 878.5284, calculated
exact mass for 6, [M + H]+ = 878.5266). The molecular formula
C47H73NO15 was obtained for the heptaene (observed mass =
892.5082, calculated exact mass for 5, [M + H]+ = 892.5058).
A crude sample of 5 had antifungal activity at a concentration
of 10 mg/ml and a crude sample of 6 was active at 5 mg/ml. Be-
cause 8-deoxy-16-descarboxyl-16-methyl-amphotericin A and
16-descarboxyl-16-methyl-amphotericin B had minimum inhibi-
tory concentrations of 5 mg/ml and 1 mg/ml, respectively, the
presence of a ketone group at C-15 causes some loss in antifun-
gal activity.
The yields were not high enough to allow purification of suffi-
cient material for NMR analysis. The purification of amphotericin
analogs critically depends on selective precipitation of the poly-
enes when methanol extracts are concentrated. This separates
polyenes from lipids and other contaminants. We have found
that when the polyene yield is below 20 mg per liter, polyenes
do not precipitate from concentrated extracts. The ratio of con-
taminants to polyenes remains high, and further purification
steps have not yielded material that gives good NMR spectra.
However, we have shown that biosynthesis of 5 and 6 is possible
and that these compounds still have antifungal activity. Attempts
to improve yields will be made in future work.
Complementation of the amphNM Deletion
Attempts were made to complement the amphNM deletion in
the DNM-KR12 strain and to generate a strain that would syn-
thesize 15-deoxy-15-oxo analogs 3 and 4 containing a carboxyl
group at C-16. The amphNM region was amplified from a cos-Chemistry & Biologymid clone (Caffrey et al., 2001) by PCR with primers
AmphNM-F and AmphNM-R. The PCR product was digested
with BglII and HindIII and ligated between the BamHI and HindIII
sites of pIAGO (Aguirrezabalaga et al., 2000), downstream from
the strong ermE promoter, to give pIAGO-amphNM. To con-
struct a second expression plasmid pIAGO-amphM, which con-
tains only the ferredoxin gene, the amplified DNA was cut with
BclI and HindIII and cloned between the BamHI and HindIII sites
of pIAGO.
The pIAGO-amphNM construct was introduced into strain
DNM-KR12 and strain DNM. Polyenes produced by strain
DNM containing pIAGO-amphNM were purified and analyzed
by ESMS. This revealed that the strain produced amphotericins
B (1) and A (2) with a 10-fold increase in yield (ca 500 mg/l) and
only traces of the descarboxyl analogs were detected (data not
shown). The fact that the plasmid-borne amphNM genes com-
plemented the chromosomal amphNM deletion showed that
the ermE promoter is functional inS. nodosus. However, no poly-
enes were produced by S. nodosus DNM-KR12 containing
pIAGO-amphNM. This suggests that compounds 3 and 4 might
be toxic to producing cells, or unstable, so it might not be possi-
ble to obtain 15-oxo-amphotericins in S. nodosus strains that
retain functional amphN and amphM genes. Thus, it was not
possible in this work to determine whether introduction of a ke-
tone at C-15 could promote loss of an exocyclic carboxyl group
by spontaneous decarboxylation.
In control experiments, the empty pIAGO vector had no effect
on polyene production by strain DNM or strain DNM-KR12. A
pIAGO construct containing amphM alone caused no change
in the pattern of polyene production by strain DNM.
Inactivation of KR16
The KC-KR16 phage was used to obtain a gene replacement
mutant in the wild-type strain (Figure 3). This mutant S. nodosus
DKR16 produced tetraene (200 mg/l) and heptaene (100 mg/l) in
yields comparable to those obtained from the wild-type strain.
Methanolic extracts of the mycelia were concentrated in vacuo
until a yellow precipitate formed that containedmostly heptaene.
Sedimentation of this precipitate by centrifugation provided
a cleaner separation of the heptaene and tetraene than wasFigure 3. Replacement of the KR16 Coding
Sequence in S. nodosus
(A) The KC-KR16 phage was used to replace the
chromosomal sequence with the engineered se-
quence via two homologous recombination events.
(B) Analysis of the KR16 coding region in the
chromosome of S. nodosus KR16. The KR16 cod-
ing region was amplified by PCR with primers
KR16checkF and KR16checkR. The PCR prod-
ucts were treated with HindIII and analyzed by
agarose gel electrophoresis. Lane M, molecular
weight markers. Lanes 1 and 2, material amplified
from genomic DNA of S. nodosus ATCC14899
and S. nodosus DKR16; lanes 3 and 4, HindIII di-
gests of DNA amplified from S. nodosus and S.
nodosus DKR16. The KR16 sequence (1576 bp)
amplified from the wild-type strain was not di-
gested with HindIII (lane 3), whereas the corresponding region from S. nodosus DKR16 was cut to give 1046 and 526 bp fragments (lane 4). A small amount
of uncut DNA in lane 4 results from amplification of the KR5 coding sequence. This KR is also preceded by an ER domain, and the KR16 primers closely match
this region. DNA amplified from S. nodosus (lane 5) and S. nodosus KR16 (lane 6) cut completely with KpnI. The KR5 and KR16 coding regions contain a con-
served KpnI site at the same position.15, 78–86, January 2008 ª2008 Elsevier Ltd All rights reserved 81
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Biosynthesis of Oxo-Amphotericinsachieved with other mutants in earlier studies. The aqueous
supernatant was removed and the tetraene was recovered by
extraction with a small volume of butanol.
The separated tetraene and the heptaene fractions were dis-
solved in methanol and further purified by gel filtration on Sepha-
dex LH20. Analysis by ESMS indicated that the major heptaene
product was 7-oxo-amphotericin B (7) ([M + H]+ = 938.7; [M +
Na]+ = 960.6; [M + K]+ = 976.6; [M  H] = 936.8) (Figures 4A
and 4B). The major tetraene was 7-oxo-amphotericin A (8) ([M +
H]+ = 940.5; [M + Na]+ = 962.5; [M + K]+ = 978.4; [M – H] =
938.6) (Figures 4C and 4D) with low levels of the 8-deoxy analog.
Whereas the presence of a ketone group at C-7 will make oxida-
tion at C-8 chemicallymuchmore facile, it remains surprising that
despite such major adjacent substrate alteration, the AmphL-
catalyzed C-8 oxidation of the heptaene is complete, although
some of the tetraene was not hydroxylated.
Analysis by high-resolution ESMS gave the molecular formula
C47H72NO18 for the DKR16 heptaene (observed mass =
938.4705, calculated mass for 7-oxo-amphotericin B (7), [M +
H]+ = 938.4749) and C47H74NO18 for the DKR16 tetraeneFigure 4. ESMS Analysis of Heptaene and
Tetraene Produced by S. nodosus KR16
(A) and (B) show analyses of the purified heptaene
in positive and negative ion modes. (C) and (D)
show analyses of the tetraene in positive and neg-
ative ion modes.
(A) Analysis in positive ion mode revealed major
species with masses of 938.7, 960.6, and 976.6
consistent with 7-oxo-amphotericin B (7), ([M +
H]+ = 938.5; [M + Na]+ = 960.5; [M + K]+ = 976.5).
An ion corresponding to a dehydrated form of
this compound was also detected ([M + H]+ =
920.7).
(B) Analysis in negative ion mode revealed a peak
of 936.8 which is also consistent with 7 ([MH] =
936.5). The peaks at 941.8 and 911.8 are contam-
inants.
(C) Analysis of the tetraene in positive ion mode
gave peaks at 940.5, 962.5, and 978.4. These
are consistent with 7-oxo-amphotericin A (8)
([M + H]+ = 940.5; [M + Na]+ = 962.5; [M + K]+ =
978.4). The peak at 924.5 is consistent with the
8-deoxy analog of 8, 8-deoxy-7-oxo-amphotericin
A ([M + H]+ = 924.5). The peak at 922.5 is a dehy-
drated form of 8.
(D) Analysis of the tetraene in negative ion mode
revealed peaks at 938.6 corresponding to 8
([M – H] = 938.5) and at 922.6 corresponding to
the 8-deoxy analog of 8 ([M  H] = 922.5).
(observed mass = 940.4882, calculated
mass for 7-oxo-amphotericin A (8), [M +
H]+ = 940.4906).
Structural Elucidation of 7-Oxo-
Amphotericin B
The crude 7-oxo-amphotericin B was
converted to the N-acetyl methyl ester
(9) and purified for analysis by 1D and
2D NMR spectroscopy (Figure 5). The82 Chemistry & Biology 15, 78–86, January 2008 ª2008 Elsevier Ltdcarbon NMR shows the expected number of resonances (except
for overlapping isochronous resonances in the polyene region),
with a resonance at 212.67 ppm confirming a ketone. In the
HMBC spectrum, there is a weak crosspeak from this carbon
to a hydrogen at 2.68 ppm. The HSQC indicates that the two
diastereotopic protons on C-6 are at 2.56 (6a) and 2.68 (6b).
The COSY spectrum shows that H-6a correlated to a CHOH
resonance at 4.08 assigned as H-5, and that this correlates to
two H-4 hydrogens at 1.34 and 1.42, which correlate to H-3 at
4.11, which correlates to H-2 at 2.12 ppm. There are several cor-
relations unobserved such as 35/36, 36/37, 18a/19, and 8/9,
presumably due to the dihedral angles involved.
The HSQC shows correlation between the downfield C-O car-
bon at 79.86 ppm assigned as C-8 and 3.74 ppm (H-8). There is
no COSY correlation between H-8 and H-9 assigned as 3.97,
which has COSY correlations to both 10a at 1.54 and 10b at
1.58, which correlate with H-11 at 4.13.
The combined NMR spectra (Supplemental Data) are strongly
consistent with the expected structure. However, in the absence
of an X-ray structure, the large number of near-isochronousAll rights reserved
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Biosynthesis of Oxo-Amphotericinsresonances in both carbon and proton NMR precludes rigorous
exclusion of regioisomers, and is not indicative of stereochemis-
try, presumed to be as for amphotericin B. Efforts are in progress
to obtain further data, and to carry out X-ray crystallographic
analysis.
The extra carbonyl group at C-7 might have a small through-
space or conformational effect upon the polyene region in the
proton NMR. In amphotericin itself there is a resonance slightly
downfield of the other polyenes, whereas in our derivatized prod-
uct this has merged into the other polyene resonances.
Analysis of Antifungal and Hemolytic Activities
of 7-Oxo-Amphotericins
For assessment of antifungal and hemolytic activities, unmodi-
fied 7-oxo-amphotericin B was purified further. Purification by
reverse-phase HPLC yielded material that was 87.5% pure. In
control assays, amphotericin B (1) showed a minimum inhibitory
concentration (MIC) of 1.25 mg/ml and aminimumhemolytic con-
centration (MHC) of 6 mg/ml. 7-oxo-amphotericin B (7) had
a lower antifungal activity (MIC = 4.5 mg/ml) but showed a greater
relative decrease in hemolytic activity (MHC= 65 mg/ml). Surpris-
ingly, tests with the tetraene 7-oxo-amphotericin A (8) could de-
tect neither antifungal activity (MIC > 166 mg/ml) nor hemolyticFigure 5. NMR Analysis of 7-Oxo-Ampho-
tericin B
(A) Structure of methyl N-acetyl-7-oxo-amphoter-
icin B.
(B) Proton NMR spectrum (400 MHz DMSO-d6).
The amide NH resonance at d 7.65 ppm is not
shown; 2.5 ppm is solvent; 3.5 ppm is water. Full
spectra are provided in the Supplemental Data.
activity (MHC > 96 mg/ml). Further work
on the conformation of this compound
will be necessary to explain this result.
DISCUSSION
In recent years there has been a dramatic
increase in life-threatening systemic my-
coses, and the emergence of resistance
to current antibiotic treatments is leading
to a crisis in antifungal therapy (Lemke
et al., 2005). Because resistance to am-
photericin B apparently does not readily
arise in fungal pathogens (Abu-Salah,
1996; Hamilton-Miller, 1973), there is
considerable interest in identifying am-
photericin analogs with reduced toxicity.
Such analogs could also be used for
treatment of other diseases.
This work has yielded four amphoteri-
cin derivatives: 5, 6, 7, and 8. As yet, it
has not been possible to engineer the
biosynthesis of analogs 3 and 4. How-
ever, sufficient 6 was obtained to show
that a ketone group at C-15 does not im-Chemistry & Biologypair antifungal activity. A ketone group at this position will allow
derivatization for production of interesting semisynthetic analogs
that have not been accessible before. Work is in progress to im-
prove the yields of compounds 5 and 6 by random mutagenesis
and by investigating fermentation conditions.
The nonaromatic heptaenes candidin and mycoheptin have
ketone groups at the carbon atoms corresponding to C-7 and
C-5 of amphotericin B, respectively (Pawlak et al., 1993; Omura
and Tanaka, 1986) (Figure 1). The 7-oxo-amphotericin B analog
(7) is structurally related to these heptaenes but has a novel extra
hydroxyl group in the polyol chain adjacent to the ketone. The
antifungal activities of candidin and mycoheptin are comparable
to that of amphotericin B (Thomas, 1976). Candidin is less hemo-
lytic than amphotericin B (Cybulska et al., 1995). Mycoheptin is
slightly less active than amphotericin B at promoting cation efflux
from muscle cells (Shvinka and Caffier, 1994). Otherwise, little
is known about the biological activities of these heptaenes.
Although 7-oxo-amphotericin B had a lower antifungal activity
than amphotericin B, it showed a greater reduction in hemolytic
activity andmight be of some therapeutic interest. The additional
ketone group should increase the polarity of the polyol chain.
Selective chemical modification of this group should allow ma-
nipulation of the transmembrane channel. It might be possible15, 78–86, January 2008 ª2008 Elsevier Ltd All rights reserved 83
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Biosynthesis of Oxo-Amphotericinsto achieve stereospecific reduction of the ketone group by
chemical means.
The 7-oxo-amphotericin A analog (8) showed a complete loss
of antifungal activity. This is surprising, because the polyene unit
of this analog is identical to that of nystatin, which is highly active.
However, some semisynthetic amphotericin derivatives are not
antifungal but retain membrane-permeabilizing activity (Zum-
buehl et al., 2004). This suggests that loss of antifungal activity
might not necessarilymean loss of other potentially useful biolog-
ical activities. The 7-oxo-amphotericins A and B have increased
water solubility and reduced hemolytic activities. These analogs
are synthesized in high yields, are easily separated, and can be
obtained in quantities sufficient for testing against parasites,
pathogenic prion proteins, and viruses.SIGNIFICANCE
This work shows that the introduction of a ketone group at
C-15 does not abolish the antifungal activity of amphotericin
B. Increased yields of these 15-deoxy-15-oxo analogs
should provide starting material for a range of interesting
semisynthetic derivatives. Introduction of ketone groups at
C-7 did not impair C-8 hydroxylation, so that 7-oxo-ampho-
tericins A and B were biosynthesized in good yield. The
7-oxo-amphotericin B analog showed decreased hemolytic
activity and retained antifungal activity. These 7-oxo analogs
can now be purified in quantities sufficient for testing in
different therapeutic areas.EXPERIMENTAL PROCEDURES
DNA Methods
EscherichiacoliXL-Blue1wasusedasahost forconstructionofplasmids.Deep
Vent, a high-fidelity DNA polymerase, was used for PCR. Resequencing of am-
plified DNA was carried out by MWG Biotech. Recombinant phages were con-
structed as described previously (Carmody et al., 2004), with KC-UCD1 as the
vector and Streptomyces lividans 1326 as host. These phages were used to in-
fect S. nodosus and S. nodosus DNM (Carmody et al., 2005). When engineered
DNA is introduced into the host cell, a double-crossover recombination event is
required to bring about gene replacement. In practice, two single-crossover
events have to be identified separately. The first recombination between phage
and chromosomal sequences brings about integration of phage DNA to form
a prophage. The host cell becomes a lysogen that can be selected because
the phage vector includes a thiostrepton-resistance gene. A phage repressor
switches off phage lytic genes. The homologous phage-borne and chromo-
somal sequencesare duplicated, in direct repeat orientation,within the lysogen.
A second recombination between these sequences results in excision of the
prophage, lossof thiostrepton resistance, andeither gene replacementor rever-
sion to the parental genotype. In this work, lysogens were subcultured three
times in the absence of antibiotic. Protoplasts were prepared to separate indi-
vidual cells from mycelial networks. Colonies derived from regenerated proto-
plasts were screened for thiostrepton sensitivity to identify recombinants that
had lost the prophage. To identify gene replacement mutants, the KR coding
sequences were amplified and tested for the presence of a HindIII site.
The KC-KR12 phage gave lysogens on both S. nodosus and S. nodosus
DNM. Sixteen thiostrepton-sensitive revertants were obtained by screening
80 clones derived from the S. nodosus DNM::KC-KR12 lysogen. Four of these
revertants were gene replacement mutants (Figure S4). Over 250 revertants of
the S. nodosus::KC-KR12 lysogen were tested, but all of these had undergone
reversion to wild-type.
The KC-KR16 phage gave a lysogen on S. nodosus. Forty thiostrepton-sen-
sitive revertants were obtained after screening 100 regenerated protoplasts.
Screening of ten revertants yielded six gene replacement mutants.84 Chemistry & Biology 15, 78–86, January 2008 ª2008 Elsevier LtdOligonucleotides AmphNM-F (50-TGACAGATCTGGACCAGGAGTTCATCA
CCG-30) and AmphNM-R (50-AAAAAAGCTTGATGTCCTGCTGATCGATCGGA
TGTGGCT-30) were used to amplify the amphNM region for subcloning. Oligo-
nucleotides KR16checkF (50-TGTTCCTCACCGCTTACCACGCGCTGAA-30)
and KR16checkR (50-AGCTCGATCGCGGTGAGCGAGTCGAA-30) were used
to amplify the KR16 coding region to identify mutants.
pIAGO is a bifunctional (Streptomyces-E. coli) plasmid that contains the pro-
moter of the erythromycin resistance gene (ermE) from Saccharopolyspora
erythraea (Aguirrezabalaga et al., 2000). It confers thiostrepton resistance in
Streptomyces and ampicillin resistance in E. coli. Transformation of S.
nodosus protoplasts was carried out as described in Kieser et al. (2000).
Initial Characterization of Polyene Products
For purification and analysis of polyenes, S. nodosus strains were grown on
fructose-dextrin (15% soluble) soya flour medium (McNamara et al., 1998)
containing Amberlite XAD16 (5% w/v). For the DNM-KR12 mutant, 100 mM
glycerol was included (Recio et al., 2006). Cultures (500 ml in 2 l flasks) were
shaken (200 rpm) at 30C for up to 5 days. Mycelia and Amberlite resin were
sedimented by centrifugation and polyenes were extracted from the pellet
with methanol (100 ml per 500 ml culture). Polyene concentrations were deter-
mined by spectrophotometry as described previously (Carmody et al., 2005).
Methanol extracts were concentrated by rotary evaporation. Polyenes precip-
itating from the aqueous residue were sedimented by centrifugation and dis-
solved in a small volume of methanol; those remaining in the aqueous layer
were extracted into a small volume of butanol. Polyenes were then partially
purified by chromatography on a Sephadex LH20 column equilibrated with
methanol (Carmody et al., 2005).
Electrospray mass spectrometry (ESMS) was carried out with a Quattro
Micro tandem quadrupole mass spectrometer (Waters Ltd., Manchester,
UK) in positive and negative ionization modes. Exact mass measurements
were determined using an online LCT (liquid chromatography to a time of flight)
instrument (Waters Ltd.). The electrospray mass spectra were acquired on the
LCT, equipped with a lockspray interface, in the positive ion mode. The sam-
ples were introduced into the ion source by an LC system (Waters Alliance
2795, Waters Ltd.) in acetonitrile:water (60:40 v/v) at 200 ml/min. The LCT
was externally calibrated for the mass range m/z 100 to m/z 1000. A lock (ref-
erence) mass (m/z 556.2771) was used.
Antifungal and hemolytic activities were assessed as described previously
(Carmody et al., 2005). For assessment of these biological activities, unmodi-
fied 7-oxo-amphotericin B (7) was further purified by reverse-phase HPLC on
a Supelco C18 column (5 mm, 21.2 mm diameter, 25 cm length). The polyene
was eluted with a gradient of 70% methanol, 30% 50 mM citrate (pH 5. 3) to
100% methanol over 12 min at a flow rate of 20 ml/min. The peak fraction
was dried down, redissolved in 50% (v/v) methanol, and desalted using
HP20 anion-exchange resin. The finalmaterial (3.2mgdryweight) gave a single
peak when rechromatographed on an analytical scale (Supplemental Data)
and was 87.5% pure as determined by gravimetric measurements.
Purification and Characterization of Methyl
N-Acetyl-7-Oxo-Amphotericin B
The KR16 mutant was grown as above (in 163 250 ml volumes of production
media containing 5% [w/v] Amberlite XAD16 resin in trigrooved 2 l flasks). The
combined mycelia and beads were extracted with methanol (2 3 2l). UV as-
say emonstrated the presence of heptaenes (350 mg) and tetraenes (1.4 g).
The combined methanolic extracts were concentrated in vacuo until a yellow
precipitate formed which was collected and washed with water (15 ml) to give
heptaenes (135mg) and tetraenes (57 mg) in a yellow powder (350mg). DMSO
(2 ml) and methanol (2 ml) were added to the resulting dried pellet and the re-
action mixture was cooled to 0C. Then acetic anhydride (0.041ml) was added
dropwise and the reaction mixture was allowed to warm to room temperature
with stirring (1 hr) and then diluted with methanol (200 ml). Excess ethereal di-
azomethane was added, and after concentration in vacuo addition of excess
ether yielded heptaenes (113 mg) and tetraenes (27 mg) as a yellow powder
(195 mg). The crude product was adsorbed onto silica gel (40–63 mm; 50 g),
and purified by flash silica chromatography. The polyene-containing fractions
(10%–20%MeOH in EtOAc) were combined and purified twice by HPLC (Var-
ian Prostar diode array with a Supelco silica column (5 mm, 21.2 mm diameter,
25 cm length, 20 ml/min flow), methanol/dichloromethane 5%–15% gradient,All rights reserved
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pure.
The physical properties were as follows: Rf 0.47 (silica, 20%MeOH in DCM);
IR (powder) nmax 3346 (s, OH), 1722 (s, C = O, ester, lactone, 7-oxo), 1653
(s, C = O, N-acetate); UV-vis (MeOH) lmax 406 (59,700), 383 (56,160), 364
(33,220), 346 (15,380); m/z (ESI) = 992.4 [(M  H), 20%]; 1028.6 [(M + Cl),
100%]; C50H74NO19 (M  H), 992.48551; found, 992.48248.
NMR spectra were recorded on a Bruker DRX 400 spectrometer with reso-
nance frequencies quoted in parts per million relative to tetramethylsilane.
Standard parameters were used for 1D and 2D NMR spectra, which included
1H, 13C (with attached proton test), 1H/1H-correlated spectroscopy (COSY),
heteronuclear single-quantum coherence (HSQC), and heteronuclear multi-
ple-bond correlation (HMBC). Full spectra and parameters used are shown
in Supplemental Data.
1HNMR (400MHzDMSO-d6) d 7.65 (d, 1H, J 8.2, NH), 6.47–6.04 (m, 10H, H-
22/H-31), 6.11 (m, 1H, H-21), 6.08 (m, 1H, 13-OH), 6.03 (t, 1H, J 10.1, H-32),
5.91 (dd, 1H, J 8.7, 15.1, H-20), 5.45 (dd, 1H, J 10.1, 15.5, H-33), 5.31 (s, 1H,
3-OH), 5.24 (d, 1H, J 5.5, 8-OH), 5.19 (m, 1H, H-37), 4.91 (d, 1H, J 6.3, 15-OH),
4.79 (d, 1H, J 5.6, 40-OH), 4.77 (m, 1H, 11-OH), 4.71 (m, 1H, 5-OH), 4.65 (d, 1H,
J 6.3, 35-OH), 4.61 (d, 2H, J 5.2, 20-OH, 9-OH), 4.35 (m, 1H, H-19), 4.30 (s, 1H,
H-10), 4.22 (t, 1H, J 9.5, H-17), 4.13 (m, 1H, H-11), 4.11 (m, 1H, H-3), 4.09 (m,
1H, H-5), 4.03 (dq, 1H, J 5.5, 10.5, H-15), 3.97 (m, 1H, H-9), 3.74 (br d, 1H, J 3.5,
H-8), 3.66 (s, 3H, OMe), 3.62 (m, 1H, H-30), 3.54 (m, 1H, H-20), 3.16 (m, 1H, H-
50), 3.12 (m, 1H, H-40), 3.08 (m, 1H, H-35), 2.68 (dd, 1H, J 8.6, 10.6, H-6b), 2.56
(m, 1H, H-6a), 2.28 (dq, 1H, J 6.1, 15.5, H-34), 2.12 (ca d, 2H, J 5.8, H-2ab),
2.07 (t, 1H, J 10.5, H-16), 1.87 (m, 1H, H-14b), 1.86 (m, 1H, H-18b), 1.85 (s,
3H, NHCOCH3), 1.72 (q, 1H, J 6.9, H-36), 1.63 (m, 1H, H-12b), 1.58 (m, 1H,
10b), 1.56 (m, 1H, 18a), 1.56 (m, 1H, 12a), 1.55 (m, 1H, 10a), 1.42 (m, 1H,
H-4b), 1.34 (m, 1H, H-4a), 1.16 (d, 3H, J 5.5, 60-CH3), 1.12 (m, 1H, H-14a),
1.11 (d, 3H, J 6.4, 38-CH3), 1.05 (d, 3H, J 6.4, 40-CH3), 0.92 (d, 3H, J 6.9,
39-CH3);
13C NMR (100.62 MHz DMSO-d6) d 212.67 (C-7), 173.28 (C-41),
171.09 (C-1), 169.74 (NHC[O]CH3), 137.16 (C-33), 136.31 (C-20), 134.67,
134.56, 133.90, 132.58 (2 C), 132.48 (2 C), 132.35 (C-21), 131.55 (C-32),
129.9, 97.88 (C-13), 97.31 (C-10), 79.86 (C-8), 78.05 (C-35), 75.00 (C-19),
74.03 (C-50 ), 70.32 (C-9), 70.14 (C-40), 69.52 (C-20), 69.44 (C-37), 66.36 (C-3),
65.84 (C-11), 65.69 (C-15), 65.60 (C-17), 57.44 (C-16), 55.45 (C-30), 52.04
(OCH3), 47.57 (C-6), 46.48 (C-12), 44.60 (C-14), 44.05 (C-4), 43.13 (C-34),
42.54 (C-2), 41.33 (C-10), 37.17 (C-18), 23.26 (NHC[O]CH3), 18.94 (C-40),
18.59 (C-60), 17.51 (C-38), 12.72 (C-39).
COSY correlations: 2/3 (H-2 to H-3), 3/4ab, 4ab/5, 5/6a, 5/6b(w), 8/8-OH,
9/10a, 9/10b(w), 9/9-OH, 10ab/11, 11/12ab, 14a/14b, 14a/15, 14b/15(w),
15/16, 15/15-OH, 16/17, 17/18a, 18b/19(w), 19/20, 32/33, 33/34, 34/40, 34/35,
36/39, 37/38, 30/40, 50/60.
HSQC (single-bond carbon/proton) correlations: 17.51/1.11 (C/H-38), 18.59/
1.16 (60), 18.94/1.05 (40), 23.26/1.85 (NHCOMe), 37.17/1.56 and 1.87 (18),
40.05/1.72 (36), 41.33/1.55 and 1.58 (10), 42.54/2.12 (2), 43.13/2.28 (34),
44.05/1.34 and 1.42 (4), 44.60/1.12 and 1.87 (14), 46.48/1.56 (12), 47.57/2.56
and 2.68 (6), 52.04/3.66 (COOMe), 55.45/3.62 (30), 57.44/2.07 (16), 65.60/
4.22 (17), 65.69/4.03 (15), 65.84/4.08 (5), 66.30/4.11 (3), 66.36/4.13 (11),
69.44/5.19 (37), 69.52/3.54 (20), 70.14/3.12 (40), 70.32/3.97 (9), 74.03/3.16 (50),
75.00/4.35 (19), 78.05/3.08 (35), 79.86/3.74 (8), 97.31/4.30 (10), 129.9/6.09
(polyene), 131.55/6.02 (32), 132–135/6.1–6.43 (polyene), 132.35/6.11 (21),
134.56/6.39 (unknown), 136.31/5.91 (20), 137.16/5.45 (33).
HMBC (multiple-bond carbon/proton) correlations: C7/H6a(w), C13/13(OH),
C14/13(OH), C15/H14a, C17/H16, C17/H18b(very weak), C19/H21, C33/H40,
C34/H40, C35/H39, C35/H40, C36/H38, C36/H39, C37/H39, C39/H38(w),
C40/H60, C50/H60, -NHCOMe, -NHCOCH3, -COOCH3, -CHCOOCH3.
Supplemental Data
Supplemental Data include 31 figures and 1 table and can be found with this
article online at http://www.chembiol.com/cgi/content/full/15/1/78/DC1/.
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